Status:
RECRUITING
Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)
Lead Sponsor:
Istituto Nazionale di Ricovero e Cura per Anziani
Conditions:
Type 2 Diabetes
Cardiovascular Complication
Eligibility:
All Genders
50+ years
Brief Summary
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic pept...
Detailed Description
This single-center, investigator-initiated, prospective observational study aims to evaluate the prognostic value of serum cardiac damage markers such as high-sensitivity cardiac troponin I (hs-cTnI),...
Eligibility Criteria
Inclusion
- type 2 diabetes
- patients attending the outpatient services
Exclusion
- type 1 diabetes
- patients with active cancer or cancer in remission for less than 5 years
- any medical or other reason that leads the investigator to consider the subject ineligible for the study.
Key Trial Info
Start Date :
April 18 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
1002 Patients enrolled
Trial Details
Trial ID
NCT06902857
Start Date
April 18 2024
End Date
December 31 2028
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS INRCA Hospital
Ancona, Italy, 60127